Moira Pinzan Rossi
YOU?
Author Swipe
View article: 358 Development of an allogenic FAP CAR iNKT product to target tumor stroma and modulate the tumor microenvironment
358 Development of an allogenic FAP CAR iNKT product to target tumor stroma and modulate the tumor microenvironment Open
Background The emergence of antibodies targeting checkpoint modulators such as PD-1 and CTLA-4 has revolutionized solid tumor treatment and highlighted the importance of effectively engaging the immune system to drive durable responses. Ho…
View article: 322 MiNK-413: a next generation armored allogenic BCMA CAR iNKT product
322 MiNK-413: a next generation armored allogenic BCMA CAR iNKT product Open
Background We are developing MiNK-413; a novel allogeneic CAR-iNKT product targeting BCMA and secreting soluble IL-15 for treatment of relapsed/refractory Multiple Myeloma (rrMM). Chimeric Antigen Receptor (CAR)-T cell therapy has revoluti…
View article: 135 Identification and characterization of an allogeneic iNKT-CAR targeting BCMA
135 Identification and characterization of an allogeneic iNKT-CAR targeting BCMA Open
Background Chimeric antigen receptor (CAR) T cell therapy has shown outstanding benefit in hematological malignancies with three autologous CAR-T therapies commercially available and several in clinical development. The use of autologous T…
View article: Foxg1 Upregulation Enhances Neocortical Activity
Foxg1 Upregulation Enhances Neocortical Activity Open
Foxg1 is an ancient transcription factor gene orchestrating a number of neurodevelopmental processes taking place in the rostral brain. In this study, we investigated its impact on neocortical activity. We found that mice overexpressing Fo…